APA (7th ed.) Citation

Gaze, M. N., Handkiewicz-Junak, D., Hladun, R., Laetsch, T. W., Sorge, C., Sparks, R., . . . Giraudet, A. (2025). Safety and dosimetry of [177Lu]Lu-DOTA-TATE in adolescent patients with somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumours, or pheochromocytomas and paragangliomas: Primary analysis of the Phase II NETTER-P study. European Journal of Nuclear Medicine & Molecular Imaging, 52(11), 4001. https://doi.org/10.1007/s00259-025-07246-7

Chicago Style (17th ed.) Citation

Gaze, Mark N., et al. "Safety and Dosimetry of [177Lu]Lu-DOTA-TATE in Adolescent Patients with Somatostatin Receptor-positive Gastroenteropancreatic Neuroendocrine Tumours, or Pheochromocytomas and Paragangliomas: Primary Analysis of the Phase II NETTER-P Study." European Journal of Nuclear Medicine & Molecular Imaging 52, no. 11 (2025): 4001. https://doi.org/10.1007/s00259-025-07246-7.

MLA (9th ed.) Citation

Gaze, Mark N., et al. "Safety and Dosimetry of [177Lu]Lu-DOTA-TATE in Adolescent Patients with Somatostatin Receptor-positive Gastroenteropancreatic Neuroendocrine Tumours, or Pheochromocytomas and Paragangliomas: Primary Analysis of the Phase II NETTER-P Study." European Journal of Nuclear Medicine & Molecular Imaging, vol. 52, no. 11, 2025, p. 4001, https://doi.org/10.1007/s00259-025-07246-7.